Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-traumatic stress status among emergency department nurses during the winter H1N1 influenza season and correlations with burnout, coping, resilience, and support.

Frontiers in psychology·2026
Same author

Shifting from Proactive to Reactive Control: Cognitive Control in Action Video Game Players with Gaming Disorder.

Behavioral sciences (Basel, Switzerland)·2026
Same author

SFQMamba: A Spatial-Frequency Deraining Framework for Robust Visual Sensing in UAV-Assisted IoT Systems.

Sensors (Basel, Switzerland)·2026
Same author

[Targeted inhibition of miR-503 upregulates Apelin expression to alleviate myocardial infarction in mice].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2026
Same author

NAV-005, a high-affinity MUC16/CA125 antagonist for the treatment of humoral immunosuppressed cancers.

BMC cancer·2026
Same author

An inulin-based fiber-rich diet alleviates doxorubicin cardiotoxicity via the fMet-KCNE2 axis to attenuate ferroptosis and oxidative stress.

Free radical biology & medicine·2026
Same journal

Why Next-generation mechanistic models Will transform drug discovery: integrating efficacy and safety.

Expert opinion on drug discovery·2026
Same journal

Toward a nuanced framework for the Medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology.

Expert opinion on drug discovery·2026
Same journal

From mitochondrial signal to discovery decision: a reserve-demand framework for translational risk assessment.

Expert opinion on drug discovery·2026
Same journal

Advances in 3D cell culture models for alzheimer's disease drug discovery.

Expert opinion on drug discovery·2026
Same journal

Are patient-derived models of amyotrophic lateral sclerosis a game changer for novel drug discovery?

Expert opinion on drug discovery·2026
Same journal

Unfolding prion misfolding and the challenge of identifying effective therapeutics: is there hope on the horizon?

Expert opinion on drug discovery·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

Reverse Genetic Morpholino Approach Using Cardiac Ventricular Injection to Transfect Multiple Difficult-to-target Tissues in the Zebrafish Larva
08:22

Reverse Genetic Morpholino Approach Using Cardiac Ventricular Injection to Transfect Multiple Difficult-to-target Tissues in the Zebrafish Larva

Published on: June 17, 2014

Developing novel biopharmaceutical products through morphogenics.

Nicholas C Nicolaides1, Phillip M Sass, Qimin Chao

  • 1Morphotek, Inc., 210 Welsh Pool Road, Exton, PA 19341, USA +1 610 423 6100 ; nicolaides@morphotek.com.

Expert Opinion on Drug Discovery
|March 16, 2013
PubMed
Summary
This summary is machine-generated.

Biologically Based Entities (BBEs) offer targeted therapies with lower toxicity. A novel platform technology called morphogenics can accelerate the development and manufacturing of these complex therapeutic molecules.

More Related Videos

A Reverse Genetic Approach to Test Functional Redundancy During Embryogenesis
06:59

A Reverse Genetic Approach to Test Functional Redundancy During Embryogenesis

Published on: August 11, 2010

Related Experiment Videos

Last Updated: May 13, 2026

Reverse Genetic Morpholino Approach Using Cardiac Ventricular Injection to Transfect Multiple Difficult-to-target Tissues in the Zebrafish Larva
08:22

Reverse Genetic Morpholino Approach Using Cardiac Ventricular Injection to Transfect Multiple Difficult-to-target Tissues in the Zebrafish Larva

Published on: June 17, 2014

A Reverse Genetic Approach to Test Functional Redundancy During Embryogenesis
06:59

A Reverse Genetic Approach to Test Functional Redundancy During Embryogenesis

Published on: August 11, 2010

Area of Science:

  • Genomics and biopharmaceutical development
  • Therapeutic target identification
  • Biologically Based Entities (BBEs)

Background:

  • The genomics era has identified numerous disease-associated loci, enabling novel biopharmaceutical targets.
  • Small chemical entities historically targeted intracellular proteins, enzymes, and channels.
  • Biologically Based Entities (BBEs) offer enhanced specificity and lower toxicity compared to small molecules.

Purpose of the Study:

  • To discuss a platform technology that addresses manufacturing challenges for Biologically Based Entities (BBEs).
  • To highlight how this technology accelerates the development of efficacious BBEs.
  • To overcome current shortfalls in producing complex biological molecules for clinical demand.

Main Methods:

  • Review of enabling platform technology: morphogenics.
  • Focus on rapid generation of robust manufacturing systems.
  • Assessment of acceleration in Biologically Based Entities (BBEs) development.

Main Results:

  • Morphogenics platform technology rapidly yields robust systems for Biologically Based Entities (BBEs) production.
  • The technology addresses manufacturing shortfalls for complex biological molecules.
  • Development of highly efficacious Biologically Based Entities (BBEs) is accelerated.

Conclusions:

  • Morphogenics is a key enabling platform technology for Biologically Based Entities (BBEs).
  • This technology overcomes manufacturing limitations and enhances therapeutic development.
  • It accelerates the creation of specific and effective Biologically Based Entities (BBEs) therapies.